logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Dcn Dx Acquires Microbiological Testing Products Company Biomed Diagnostics

Apr 25, 2022•over 3 years ago

Acquiring Company

DCN Dx

Acquired Company

Biomed Diagnostics

Science And EngineeringData And AnalyticsHealth Care

Description

DCN Dx, a global leader in the end-to-end development, manufacture, and commercialization of point-of-use tests, today announced it has completed its acquisition of Biomed Diagnostics, Inc., a microbiological testing products company based in White City, Oregon.

Company Information

Company

DCN Dx

About

CN Dx is a global leader in the end-to-end development, manufacture, and commercialization of point-of-use tests. From its headquarters in Carlsbad, California, DCN Dx's cross-functional team of scientists and engineers develop and integrate all aspects of assays into reliable systems for point-of-use applications that enable users to monitor sample quality, identify pathogens, and facilitate the delivery of treatments. DCN Dx partners with industry leaders to develop point-of-use tests, train users in diagnostic development, and carry out clinical research for medical point-of-care testing, veterinary diagnostics, soil and water testing, bioprocessing, food safety, force protection, and more. To learn more about DCN Dx's products and services, click here. MEDIA CONTACT: John L. Tonkinson, Ph.D.Chief Strategy Officer, DCN DxMain: (760) 804-3886 Mobile: (860) 977-4012 334866@email4pr.com SOURCE DCN Dx

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed